脑转移瘤的立体定向放射外科治疗:一项回顾性研究
该回顾性研究分析了2014年9月至2021年12月接受单次18 Gy立体定向放射外科治疗的72例患者共111个脑转移瘤,评估局部无进展生存、首次随访MRI反应及放射性坏死。中位局部无进展生存期为23.5个月,12个月局部无进展生存率为65.3%,放射性坏死发生率为7.2%。GTV>0.3 cm³及黑色素瘤、肾细胞癌、肉瘤组织学与较差的局部无进展生存相关。
要点
- 单次18 Gy立体定向放射外科治疗脑转移瘤的12个月局部无进展生存率为65.3%。
- 放射性坏死发生率为7.2%,中位出现时间18.4个月。
- GTV>0.3 cm³及黑色素瘤、肾细胞癌、肉瘤组织学与较差的局部无进展生存相关。
核心结论
- 作者认为,放射敏感组织学的脑转移瘤可获得合理的1年局部控制,而放射抵抗转移瘤的局部控制相对较差。
- 作者提出,治疗改进值得探索以改善脑转移瘤的局部控制。
研究设计与样本
- 回顾性研究纳入2014年9月至2021年12月接受立体定向放射外科治疗的72例患者共111个脑转移瘤。
- 处方剂量为单次18 Gy,部分I给予18 Gy至覆盖80%等剂量线并归一化至Dmax=100%即22.5 Gy,部分II给予18 Gy=D98并接受D0.03 cc为21.6-22.5 Gy。
- 研究回顾性评估局部无进展生存、首次随访MRI反应及放射性坏死。
- 本研究为回顾性注册,伦理批准编号23-3451-104。
主要发现
- 黑色素瘤脑转移瘤最常见(n=44),中位GTV为0.30 cm³(IQR 0.17-0.61),所有患者中位随访时间为50.8个月(IQR 30.4-64.6)。
- 中位局部无进展生存期为23.5个月(95%CI 17.2, 29.8),12、18、24和30个月的总局部无进展生存率分别为65.3%、56.3%、46.5%和38.8%。
- 放射抵抗组织学(黑色素瘤、肾细胞癌和肉瘤)脑转移瘤的12个月局部无进展生存率为60.2%,其他组织学为70.1%。
- 首次随访MRI在中位47天(IQR 40-63)进行,其反应对长期局部控制和生存至关重要。
- 8个脑转移瘤(7.2%)在中位18.4个月(IQR 9.4-26.5)后发生放射性坏死。
关键数值与推荐
- 多变量分析中,GTV>0.3 cm³对局部无进展生存有负面影响(HR 2.229,95%CI 1.172, 4.239)。
- 黑色素瘤、肾细胞癌和肉瘤与其他癌症类型相比局部无进展生存机会更低(HR 2.330,95%CI 1.155, 4.699)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Single-fraction stereotactic radiosurgery (SRS) is an established standard for radiation therapy of brain metastases although recent developments indicate that multi-fractionated stereotactic radiotherapy (FSRT) results in lower radiation necrosis especially for larger metastases, and the same or even better local control in comparison to SRS. METHODS: Seventy-two patients with 111 brain metastases received SRS with a single dose of 18 Gy between September 2014 and December 2021. The dose prescription was either 18 Gy given to the enclosing 80% isodose with a normalization to Dmax = 100% of 22.5 Gy (part I) or 18 Gy = D98, while D0.03 cc of 21.6-22.5 Gy was accepted (part II). The study retrospectively evaluated local progression-free survival (LPFS), response on the first follow-up magnetic resonance imaging (MRI), and radiation necrosis. RESULTS: Melanoma brain metastases (n = 44) were the most frequent metastases. The median gross tumor volume (GTV) was 0.30 cm³ (IQR, 0.17-0.61). The median follow-up time of all patients was 50.8 months (IQR, 30.4-64.6). Median LPFS was 23.5 months (95%CI 17.2, 29.8). The overall LPFS rates at 12-, 18-, 24- and 30 months were 65.3%, 56.3%, 46.5%, and 38.8%. Brain metastases with radioresistant histology (melanoma, renal cell cancer, and sarcoma) showed a 12-month LPFS of 60.2%, whereas brain metastases with other histology had a 12-month LPFS of 70.1%. The response of brain metastases on first follow-up MRIs performed after a median time of 47 days (IQR, 40-63) was crucial for long-term local control and survival. Eight brain metastases (7.2%) developed radiation necrosis after a median time of 18.4 months (IQR, 9.4-26.5). In multivariate analyses, a GTV > 0.3 cm³ negatively affected LPFS (HR 2.229, 95%CI 1.172, 4.239). Melanoma, renal cell cancers, and sarcoma had a lower chance of LPFS in comparison to other cancer types (HR 2.330, 95%CI 1.155, 4.699). CONCLUSIONS: Our results indicate a reasonable 1-year local control of brain metastases with radiosensitive histology. Radioresistant metastases show a comparatively poor local control. Treatment refinements merit exploration to improve local control of brain metastases. TRIAL REGISTRATION: This study is retrospectively registered (ethics approval number 23-3451-104).
引用
- Gruber I, Weidner K, Treutwein M, et al. Stereotactic radiosurgery of brain metastases: a retrospective study. Radiat Oncol. 2023. PMID: 38115009. doi:10.1186/s13014-023-02389-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。